These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 28741260)

  • 1. The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer.
    Wellberg EA; Checkley LA; Giles ED; Johnson SJ; Oljira R; Wahdan-Alaswad R; Foright RM; Dooley G; Edgerton SM; Jindal S; Johnson GC; Richer JK; Kabos P; Thor AD; Schedin P; MacLean PS; Anderson SM
    Horm Cancer; 2017 Dec; 8(5-6):269-285. PubMed ID: 28741260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
    Cochrane DR; Bernales S; Jacobsen BM; Cittelly DM; Howe EN; D'Amato NC; Spoelstra NS; Edgerton SM; Jean A; Guerrero J; Gómez F; Medicherla S; Alfaro IE; McCullagh E; Jedlicka P; Torkko KC; Thor AD; Elias AD; Protter AA; Richer JK
    Breast Cancer Res; 2014 Jan; 16(1):R7. PubMed ID: 24451109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperative Dynamics of AR and ER Activity in Breast Cancer.
    D'Amato NC; Gordon MA; Babbs B; Spoelstra NS; Carson Butterfield KT; Torkko KC; Phan VT; Barton VN; Rogers TJ; Sartorius CA; Elias A; Gertz J; Jacobsen BM; Richer JK
    Mol Cancer Res; 2016 Nov; 14(11):1054-1067. PubMed ID: 27565181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A surprising link between the energetics of ovariectomy-induced weight gain and mammary tumor progression in obese rats.
    MacLean PS; Giles ED; Johnson GC; McDaniel SM; Fleming-Elder BK; Gilman KA; Andrianakos AG; Jackman MR; Shroyer KR; Schedin PJ
    Obesity (Silver Spring); 2010 Apr; 18(4):696-703. PubMed ID: 19798068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer.
    Giles ED; Wellberg EA; Astling DP; Anderson SM; Thor AD; Jindal S; Tan AC; Schedin PS; Maclean PS
    Cancer Res; 2012 Dec; 72(24):6490-501. PubMed ID: 23222299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventing ovariectomy-induced weight gain decreases tumor burden in rodent models of obesity and postmenopausal breast cancer.
    Wellberg EA; Corleto KA; Checkley LA; Jindal S; Johnson G; Higgins JA; Obeid S; Anderson SM; Thor AD; Schedin PJ; MacLean PS; Giles ED
    Breast Cancer Res; 2022 Jun; 24(1):42. PubMed ID: 35725493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers.
    Secreto G; Venturelli E; Meneghini E; Carcangiu ML; Paolini B; Agresti R; Pellitteri C; Berrino F; Gion M; Cogliati P; Saragò G; Micheli A
    BMC Cancer; 2012 Dec; 12():599. PubMed ID: 23241075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmenopausal obesity promotes tumor angiogenesis and breast cancer progression in mice.
    Gu JW; Young E; Patterson SG; Makey KL; Wells J; Huang M; Tucker KB; Miele L
    Cancer Biol Ther; 2011 May; 11(10):910-7. PubMed ID: 21451264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
    Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
    J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
    Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
    Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of androgen receptor splice variants in clinical breast cancers.
    Hickey TE; Irvine CM; Dvinge H; Tarulli GA; Hanson AR; Ryan NK; Pickering MA; Birrell SN; Hu DG; Mackenzie PI; Russell R; Caldas C; Raj GV; Dehm SM; Plymate SR; Bradley RK; Tilley WD; Selth LA
    Oncotarget; 2015 Dec; 6(42):44728-44. PubMed ID: 26554309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor-mediated pharmacogenomic expression quantitative trait loci: implications for breast cancer response to AR-targeting therapy.
    Gao H; Wei L; Indulkar S; Nguyen TTL; Liu D; Ho MF; Zhang C; Li H; Weinshilboum RM; Ingle JN; Wang L
    Breast Cancer Res; 2024 Jul; 26(1):111. PubMed ID: 38965614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    Hoffmann J; Sommer A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes.
    Rajarajan S; Korlimarla A; Alexander A; Anupama CE; Ramesh R; Srinath BS; Sridhar TS; Prabhu JS
    Front Endocrinol (Lausanne); 2021; 12():679756. PubMed ID: 34234742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promotion of estrogen-induced mammary gland carcinogenesis by androgen in the male Noble rat: probable mediation by steroid receptors.
    Liao DZ; Pantazis CG; Hou X; Li SA
    Carcinogenesis; 1998 Dec; 19(12):2173-80. PubMed ID: 9886575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
    Gucalp A; Tolaney S; Isakoff SJ; Ingle JN; Liu MC; Carey LA; Blackwell K; Rugo H; Nabell L; Forero A; Stearns V; Doane AS; Danso M; Moynahan ME; Momen LF; Gonzalez JM; Akhtar A; Giri DD; Patil S; Feigin KN; Hudis CA; Traina TA;
    Clin Cancer Res; 2013 Oct; 19(19):5505-12. PubMed ID: 23965901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression.
    Christenson JL; Butterfield KT; Spoelstra NS; Norris JD; Josan JS; Pollock JA; McDonnell DP; Katzenellenbogen BS; Katzenellenbogen JA; Richer JK
    Horm Cancer; 2017 Apr; 8(2):69-77. PubMed ID: 28194662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of androgens in mammary carcinogenesis.
    Wong YC; Xie B
    Ital J Anat Embryol; 2001; 106(2 Suppl 1):111-25. PubMed ID: 11729946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells.
    Caiazza F; Murray A; Madden SF; Synnott NC; Ryan EJ; O'Donovan N; Crown J; Duffy MJ
    Endocr Relat Cancer; 2016 Apr; 23(4):323-34. PubMed ID: 26932782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional characterization of androgen receptor in two patient-derived xenograft models of triple negative breast cancer.
    Wang X; Petrossian K; Huang MJ; Saeki K; Kanaya N; Chang G; Somlo G; Chen S
    J Steroid Biochem Mol Biol; 2021 Feb; 206():105791. PubMed ID: 33271252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.